Bone Biologics Co. (NASDAQ:BBLG) Short Interest Update

Bone Biologics Co. (NASDAQ:BBLG) saw a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 193,300 shares, a growth of 48.2% from the February 13th total of 130,400 shares. Currently, 36.2% of the shares of the stock are sold short. Based on an average trading volume of 218,900 shares, the days-to-cover ratio is presently 0.9 days.

Bone Biologics Stock Performance

BBLG stock opened at $0.83 on Monday. The firm has a 50 day moving average of $0.99 and a 200-day moving average of $1.27. Bone Biologics has a 12 month low of $0.71 and a 12 month high of $4.25.

About Bone Biologics

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.